1- [2- (2,4-Dimethylphenylsulfanyl)-PHENYL] Piperazine as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 10 of these applications claim priority to application PCT/DK2007/050075, filed Jun 15, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,969,355 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence UsedRemaining | H. Lundbeck A/S | In force | High confidence | ||
| US 9,095,588 | Process for Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENY]PIPERAZINE or Pharmaceutically Acceptable Salt Thereof In force · Medium confidence | H. Lundbeck A/S | In force | Medium confidence | ||
| US 9,101,626 | Process For Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine Or Pharmaceutically Acceptable Salt Thereof In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| US 9,125,908 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| US 9,125,909 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | H. Lundbeck A/S | In force | Medium confidence | ||
| US 9,125,910 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | H. Lundbeck A/S | In force | Medium confidence | ||
| US 9,227,946 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| US 9,861,630 | 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| US 11,458,134 | 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENYL]PIPERAZINE as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| US 8,722,684 | 1- [2- (2,4-Dimethylphenylsulfanyl)-PHENYL] Piperazine as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment In force · High confidence | H. Lundbeck A/S | In force | High confidence | ||
| 3 more records in this group · Pro | ||||||
10 of 13 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 13, including 9 expiring within the 18 months from Nov 19, 2026.
10 of these are in force and held by H. Lundbeck A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.